Lisata Therapeutics, Inc. (LSTA)
USD 1.95
(-2.86%)
USD 1.95
(-2.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -22.28 Million USD | 29.62% |
| 2022 | -31.66 Million USD | -32.32% |
| 2021 | -23.93 Million USD | -50.64% |
| 2020 | -15.88 Million USD | -16.16% |
| 2019 | -13.67 Million USD | -32.81% |
| 2018 | -10.29 Million USD | 64.49% |
| 2017 | -29 Million USD | -266.48% |
| 2016 | -7.91 Million USD | -123.39% |
| 2015 | -3.54 Million USD | -39.95% |
| 2014 | -2.53 Million USD | 93.97% |
| 2013 | -41.98 Million USD | -323.03% |
| 2012 | -9.92 Million USD | -6427.94% |
| 2011 | -152.03 Thousand USD | 94.95% |
| 2010 | -3 Million USD | -162.29% |
| 2009 | 4.83 Million USD | 1261.33% |
| 2008 | -416.06 Thousand USD | 81.39% |
| 2007 | -2.23 Million USD | -1390.77% |
| 2006 | -149.94 Thousand USD | -7.72% |
| 2005 | -139.2 Thousand USD | -125.72% |
| 2004 | 541.25 Thousand USD | 172.58% |
| 2003 | 198.56 Thousand USD | 44.04% |
| 2002 | 137.85 Thousand USD | 7189.95% |
| 2001 | 1891.00 USD | 100.48% |
| 2000 | -396.41 Thousand USD | 74.26% |
| 1999 | -1.54 Million USD | -700.52% |
| 1998 | -192.4 Thousand USD | -149.74% |
| 1997 | 386.83 Thousand USD | 368.53% |
| 1996 | 82.56 Thousand USD | -98.69% |
| 1995 | 6.3 Million USD | 36.96% |
| 1994 | 4.6 Million USD | 0.0% |
| 1990 | 2 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -21.54 Million USD | 3.35% |
| 2024 Q2 | -28.07 Million USD | -30.31% |
| 2023 Q2 | -23.3 Million USD | 15.96% |
| 2023 FY | -22.28 Million USD | 29.62% |
| 2023 Q1 | -27.73 Million USD | 12.43% |
| 2023 Q4 | -22.28 Million USD | 30.92% |
| 2023 Q3 | -32.26 Million USD | -38.43% |
| 2022 FY | -31.66 Million USD | -32.32% |
| 2022 Q2 | -32.78 Million USD | -170.5% |
| 2022 Q4 | -31.66 Million USD | -2.39% |
| 2022 Q3 | -30.93 Million USD | 5.66% |
| 2022 Q1 | -12.12 Million USD | 49.35% |
| 2021 Q1 | -28.2 Million USD | -77.54% |
| 2021 FY | -23.93 Million USD | -50.64% |
| 2021 Q2 | -12.49 Million USD | 55.72% |
| 2021 Q3 | -12.42 Million USD | 0.54% |
| 2021 Q4 | -23.93 Million USD | -92.67% |
| 2020 Q4 | -15.88 Million USD | 22.29% |
| 2020 Q3 | -20.44 Million USD | 21.03% |
| 2020 Q2 | -25.89 Million USD | -26.87% |
| 2020 Q1 | -20.4 Million USD | -49.19% |
| 2020 FY | -15.88 Million USD | -16.16% |
| 2019 Q3 | -12.3 Million USD | -8.21% |
| 2019 FY | -13.67 Million USD | -32.81% |
| 2019 Q4 | -13.67 Million USD | -11.15% |
| 2019 Q1 | -14.02 Million USD | -36.21% |
| 2019 Q2 | -11.37 Million USD | 18.93% |
| 2018 Q1 | -21.5 Million USD | 25.84% |
| 2018 FY | -10.29 Million USD | 64.49% |
| 2018 Q3 | -14.37 Million USD | 36.68% |
| 2018 Q2 | -22.7 Million USD | -5.55% |
| 2018 Q4 | -10.29 Million USD | 28.35% |
| 2017 Q3 | -14.71 Million USD | 33.08% |
| 2017 FY | -29 Million USD | -266.48% |
| 2017 Q1 | -5.87 Million USD | 25.79% |
| 2017 Q2 | -21.99 Million USD | -274.49% |
| 2017 Q4 | -29 Million USD | -97.06% |
| 2016 Q3 | -11.98 Million USD | -55.36% |
| 2016 FY | -7.91 Million USD | -123.39% |
| 2016 Q2 | -7.71 Million USD | 48.45% |
| 2016 Q1 | -14.96 Million USD | -322.44% |
| 2016 Q4 | -7.91 Million USD | 33.97% |
| 2015 Q3 | -7.21 Million USD | 62.17% |
| 2015 Q1 | -2.4 Million USD | 4.9% |
| 2015 Q4 | -3.54 Million USD | 50.91% |
| 2015 FY | -3.54 Million USD | -39.95% |
| 2015 Q2 | -19.07 Million USD | -692.3% |
| 2014 FY | -2.53 Million USD | 93.97% |
| 2014 Q4 | -2.53 Million USD | 83.33% |
| 2014 Q2 | -27.92 Million USD | 23.43% |
| 2014 Q1 | -36.46 Million USD | 13.14% |
| 2014 Q3 | -15.18 Million USD | 45.61% |
| 2013 Q2 | -10.87 Million USD | -95.46% |
| 2013 Q4 | -41.98 Million USD | -225.29% |
| 2013 Q3 | -12.9 Million USD | -18.65% |
| 2013 Q1 | -5.56 Million USD | 43.92% |
| 2013 FY | -41.98 Million USD | -323.03% |
| 2012 Q2 | 1.64 Million USD | 179.1% |
| 2012 Q3 | -1.71 Million USD | -204.43% |
| 2012 Q4 | -9.92 Million USD | -479.26% |
| 2012 FY | -9.92 Million USD | -6427.94% |
| 2012 Q1 | -2.07 Million USD | -166.59% |
| 2011 Q3 | 3.53 Million USD | -79.97% |
| 2011 Q2 | 17.66 Million USD | 79.23% |
| 2011 Q1 | 9.85 Million USD | 427.39% |
| 2011 FY | -152.03 Thousand USD | 94.95% |
| 2011 Q4 | 3.11 Million USD | -11.97% |
| 2010 Q4 | -3 Million USD | -128.53% |
| 2010 Q3 | 10.55 Million USD | 35.3% |
| 2010 Q1 | 10.83 Million USD | 124.3% |
| 2010 FY | -3 Million USD | -162.29% |
| 2010 Q2 | 7.79 Million USD | -28.04% |
| 2009 Q1 | 842.63 Thousand USD | 302.53% |
| 2009 FY | 4.83 Million USD | 1261.33% |
| 2009 Q4 | 4.83 Million USD | 184.74% |
| 2009 Q2 | -10.4 Million USD | -1335.19% |
| 2009 Q3 | -5.7 Million USD | 45.21% |
| 2008 Q4 | -416.06 Thousand USD | 45.43% |
| 2008 Q3 | -762.46 Thousand USD | -67.35% |
| 2008 Q1 | -855.25 Thousand USD | 61.74% |
| 2008 FY | -416.06 Thousand USD | 81.39% |
| 2008 Q2 | -455.62 Thousand USD | 46.73% |
| 2007 Q4 | -2.23 Million USD | 36.64% |
| 2007 Q1 | -787.66 Thousand USD | -425.3% |
| 2007 FY | -2.23 Million USD | -1390.77% |
| 2007 Q3 | -3.52 Million USD | -3290.96% |
| 2007 Q2 | 110.55 Thousand USD | 114.04% |
| 2006 Q2 | -11.81 Thousand USD | -101.26% |
| 2006 FY | -149.94 Thousand USD | -7.72% |
| 2006 Q4 | -149.94 Thousand USD | 85.53% |
| 2006 Q3 | -1.03 Million USD | -8670.12% |
| 2006 Q1 | 939.1 Thousand USD | 774.62% |
| 2005 Q1 | 541.62 Thousand USD | 0.07% |
| 2005 Q4 | -139.2 Thousand USD | -121.83% |
| 2005 FY | -139.2 Thousand USD | -125.72% |
| 2005 Q3 | 637.62 Thousand USD | 1.57% |
| 2005 Q2 | 627.74 Thousand USD | 15.9% |
| 2004 Q3 | 198.85 Thousand USD | -63.05% |
| 2004 Q2 | 538.25 Thousand USD | 7.67% |
| 2004 Q1 | 499.9 Thousand USD | 151.76% |
| 2004 Q4 | 541.25 Thousand USD | 172.18% |
| 2004 FY | 541.25 Thousand USD | 172.58% |
| 2003 Q4 | 198.56 Thousand USD | -50.7% |
| 2003 Q3 | 402.78 Thousand USD | 28.44% |
| 2003 Q2 | 313.6 Thousand USD | 59.38% |
| 2003 Q1 | 196.76 Thousand USD | 42.74% |
| 2003 FY | 198.56 Thousand USD | 44.04% |
| 2002 FY | 137.85 Thousand USD | 7189.95% |
| 2002 Q4 | 137.85 Thousand USD | 22.63% |
| 2002 Q3 | 112.41 Thousand USD | 230.48% |
| 2002 Q2 | 34.01 Thousand USD | 487.78% |
| 2002 Q1 | 5787.00 USD | 206.03% |
| 2001 Q3 | -64.9 Thousand USD | -511.06% |
| 2001 Q4 | 1891.00 USD | 102.91% |
| 2001 FY | 1891.00 USD | 100.48% |
| 2001 Q1 | 25.99 Thousand USD | 106.56% |
| 2001 Q2 | -10.62 Thousand USD | -140.86% |
| 2000 Q1 | -1.43 Million USD | -104.55% |
| 2000 FY | -396.41 Thousand USD | 74.26% |
| 2000 Q4 | -396.41 Thousand USD | 62.71% |
| 2000 Q3 | -1.06 Million USD | -6.91% |
| 2000 Q2 | -994.2 Thousand USD | 30.57% |
| 1999 Q4 | -700 Thousand USD | -200.0% |
| 1999 FY | -1.54 Million USD | -700.52% |
| 1999 Q1 | 600 Thousand USD | 0.0% |
| 1999 Q3 | 700 Thousand USD | 40.0% |
| 1999 Q2 | 500 Thousand USD | -16.67% |
| 1998 FY | -192.4 Thousand USD | -149.74% |
| 1997 Q1 | 1.3 Million USD | 18.18% |
| 1997 FY | 386.83 Thousand USD | 368.53% |
| 1996 Q2 | 1 Million USD | 0.0% |
| 1996 Q4 | 1.1 Million USD | 0.0% |
| 1996 FY | 82.56 Thousand USD | -98.69% |
| 1996 Q1 | 1 Million USD | 0.0% |
| 1996 Q3 | 1.1 Million USD | 10.0% |
| 1995 Q2 | 7.1 Million USD | 0.0% |
| 1995 Q3 | 7.4 Million USD | 4.23% |
| 1995 Q1 | 7.1 Million USD | 0.0% |
| 1995 FY | 6.3 Million USD | 36.96% |
| 1995 Q4 | 1 Million USD | -86.49% |
| 1994 FY | 4.6 Million USD | 0.0% |
| 1990 FY | 2 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Keros Therapeutics, Inc. | -316.7 Million USD | 92.962% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 101.192% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -32.754% |
| AlloVir, Inc. | -62.69 Million USD | 64.448% |
| Precigen, Inc. | -481 Thousand USD | -4533.68% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 87.281% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -861.922% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -20.347% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -280.341% |
| Acelyrin, Inc. | -216.9 Million USD | 89.724% |
| AbCellera Biologics Inc. | -55.94 Million USD | 60.157% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 120.103% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 268.351% |
| Agenus Inc. | 274.13 Million USD | 108.13% |
| Dyadic International, Inc. | -6.37 Million USD | -249.446% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -39.886% |
| Lantern Pharma Inc. | -21.7 Million USD | -2.694% |
| Immix Biopharma, Inc. | -17.5 Million USD | -27.289% |
| IO Biotech, Inc. | -140.69 Million USD | 84.159% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 283.24% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 71.223% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 82.738% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 60.103% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 136.384% |
| Alkermes plc | -166.73 Million USD | 86.633% |
| Aptorum Group Limited | 1.35 Million USD | 1742.391% |
| Ardelyx, Inc. | 34.51 Million USD | 164.58% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 620.748% |
| Bicycle Therapeutics plc | -481.46 Million USD | 95.371% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 161.632% |
| Chimerix, Inc. | -25.51 Million USD | 12.654% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 419.859% |
| CRISPR Therapeutics AG | -150.84 Million USD | 85.225% |
| Elevation Oncology, Inc. | -19.11 Million USD | -16.581% |
| ESSA Pharma Inc. | -33.62 Million USD | 33.709% |
| Fortress Biotech, Inc. | 7.66 Million USD | 390.776% |
| Fortress Biotech, Inc. | 7.66 Million USD | 390.776% |
| NextCure, Inc. | -6.47 Million USD | -244.11% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 55.866% |
| Onconetix, Inc. | 5.33 Million USD | 518.049% |
| Opthea Limited | 28.15 Million USD | 179.155% |
| PDS Biotechnology Corporation | -32.7 Million USD | 31.86% |
| GT Biopharma, Inc. | -1.02 Million USD | -2082.958% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 79.837% |
| ImmuCell Corporation | 10.99 Million USD | 302.792% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 85.541% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -160.887% |
| Incyte Corporation | -3.17 Billion USD | 99.298% |
| Jaguar Health, Inc. | 29.39 Million USD | 175.833% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 517.613% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -354.023% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -60.855% |
| ContextLogic Inc. | -232 Million USD | 90.393% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 228.996% |
| MiMedx Group, Inc. | -33.9 Million USD | 34.256% |
| MEI Pharma, Inc. | -3.7 Million USD | -501.565% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 318.617% |
| Seer, Inc. | -4.24 Million USD | -425.66% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -297.272% |
| Novavax, Inc. | -298.29 Million USD | 92.528% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 258.284% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -249.396% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 26.829% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 86.752% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 113.78% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 423.268% |
| Vaxcyte, Inc. | -368.22 Million USD | 93.947% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 59.924% |
| Pharming Group N.V. | 109.8 Million USD | 120.298% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 90.804% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -28.121% |
| PureTech Health plc | -167.19 Million USD | 86.67% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 180.193% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -20.347% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -213.915% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -1192.807% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -227.62% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1380.92% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 87.927% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -267.667% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 22439.604% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 3649.045% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 7.276% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 80.958% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 278.147% |
| ChromaDex Corporation | -24.04 Million USD | 7.319% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -193.418% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 5.866% |
| Precision BioSciences, Inc. | -85.41 Million USD | 73.905% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 136.143% |
| Innoviva, Inc. | 255.56 Million USD | 108.721% |
| Summit Therapeutics Inc. | 34.67 Million USD | 164.279% |
| GlycoMimetics, Inc. | -40.98 Million USD | 45.618% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 67.119% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 83.377% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 22.804% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -29485.579% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 27.782% |
| Aptose Biosciences Inc. | -8.19 Million USD | -171.975% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -612.3% |
| Soligenix, Inc. | -4.95 Million USD | -350.117% |
| Century Therapeutics, Inc. | 847 Thousand USD | 2731.405% |
| Kura Oncology, Inc. | -20.11 Million USD | -10.786% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 45.541% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -165.397% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1323.476% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -597.154% |
| Autolus Therapeutics plc | -186.59 Million USD | 88.056% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 54.795% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 91.919% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 165.04% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 113.56% |
| GRI Bio, Inc. | -1.79 Million USD | -1142.363% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -148.112% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 32.983% |
| IGM Biosciences, Inc. | -72.6 Million USD | 69.303% |
| INmune Bio, Inc. | -25.41 Million USD | 12.29% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 114.765% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 56.004% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -37.162% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -672.567% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 158.629% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 45.883% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 169.901% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 105.897% |
| Verastem, Inc. | -37.27 Million USD | 40.211% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -145.652% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 57.024% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -47.261% |
| Histogen Inc. | -7.48 Million USD | -197.689% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -3.153% |
| Surrozen, Inc. | -32.66 Million USD | 31.766% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1378.965% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -430.226% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 217.551% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 951.988% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 636.285% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -165.93% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 48.695% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -52.9% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 92.964% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -2986.724% |
| Apollomics, Inc. | -27.39 Million USD | 18.642% |
| Amarin Corporation plc | -191.04 Million USD | 88.333% |
| Mesoblast Limited | 55.96 Million USD | 139.826% |
| Turnstone Biologics Corp. | -14.58 Million USD | -52.825% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 11.877% |
| Synaptogenix, Inc. | -28.66 Million USD | 22.237% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -2281.197% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 145.736% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -2485.348% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -206.74% |
| Exelixis, Inc. | -73.05 Million USD | 69.489% |
| Better Therapeutics, Inc. | -860 Thousand USD | -2491.628% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 7.184% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 90.766% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 3127.989% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -199.645% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 1877.352% |
| Gritstone bio, Inc. | 39.49 Million USD | 156.44% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 73.499% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -746.763% |
| Avid Bioservices, Inc. | 169.72 Million USD | 113.132% |
| Insmed Incorporated | 721.62 Million USD | 103.089% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -143.811% |
| MediWound Ltd. | -5.32 Million USD | -318.79% |
| OmniAb, Inc. | 9.2 Million USD | 342.182% |
| Alector, Inc. | -35.63 Million USD | 37.458% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 125.925% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -352.273% |
| Zai Lab Limited | -775 Million USD | 97.124% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 106.545% |
| Aura Biosciences, Inc. | -21.52 Million USD | -3.545% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 72.978% |
| Immunic, Inc. | -45.34 Million USD | 50.843% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 88.465% |
| Veracyte, Inc. | -203.82 Million USD | 89.065% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 103.492% |
| FibroGen, Inc. | 56.76 Million USD | 139.262% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 350.286% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -688.375% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -976.534% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.486% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -567.106% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 86.571% |
| TG Therapeutics, Inc. | 17.86 Million USD | 224.779% |
| Galecto, Inc. | -21.21 Million USD | -5.053% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 6.294% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.42% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 8.924% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -93.691% |
| XBiotech Inc. | -200.02 Million USD | 88.857% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 73.499% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 592.226% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 36.795% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 71.136% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 491.636% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 86.921% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 75.872% |
| Vaxxinity, Inc. | 10.13 Million USD | 319.976% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 103.027% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -106.992% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 66.208% |
| NexImmune, Inc. | -3.13 Million USD | -611.249% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -545.529% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -47.491% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 17.756% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -148.305% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -17791.23% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 45.066% |
| Ainos, Inc. | 4.07 Million USD | 646.552% |
| Pluri Inc. | 22.82 Million USD | 197.63% |
| Prothena Corporation plc | -608.34 Million USD | 96.336% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 81.232% |
| Celularity Inc. | 65.19 Million USD | 134.189% |
| Rallybio Corporation | -24.1 Million USD | 7.526% |
| Cue Biopharma, Inc. | -33.81 Million USD | 34.096% |
| MeiraGTx Holdings plc | -40.3 Million USD | 44.698% |
| Omeros Corporation | 331.17 Million USD | 106.73% |
| Humacyte, Inc. | -22.48 Million USD | 0.881% |
| Immunocore Holdings plc | -358.59 Million USD | 93.785% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 9.306% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 27.873% |
| Blueprint Medicines Corporation | 702.83 Million USD | 103.171% |
| CalciMedica, Inc. | -5.53 Million USD | -303.038% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 88.159% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -118.21% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 44.331% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 32.974% |
| Pulmatrix, Inc. | -10.41 Million USD | -113.958% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -272.896% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 41.566% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 79.993% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 62.819% |
| Cytokinetics, Incorporated | 642.37 Million USD | 103.47% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -282.758% |
| Nutriband Inc. | -251.65 Thousand USD | -8756.499% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 34.676% |
| Vor Biopharma Inc. | 4.3 Million USD | 618.326% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.631% |
| Evogene Ltd. | -19.63 Million USD | -13.517% |
| ProKidney Corp. | -56.23 Million USD | 60.367% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 54.208% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -141.286% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.634% |
| CorMedix Inc. | -43.05 Million USD | 48.231% |
| BioLineRx Ltd. | 7.33 Million USD | 403.817% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 18.849% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 148.298% |
| Atai Life Sciences N.V. | -28.55 Million USD | 21.955% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 1099.225% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 2.314% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 225.672% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 70.312% |
| MediciNova, Inc. | -50.78 Million USD | 56.112% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 71.718% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -98979.796% |
| GeoVax Labs, Inc. | -6.45 Million USD | -245.412% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 88.846% |
| Biomea Fusion, Inc. | -166.57 Million USD | 86.619% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 87.547% |
| Mereo BioPharma Group plc | -51.46 Million USD | 56.696% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 76.5% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 92.413% |
| Absci Corporation | -72.59 Million USD | 69.299% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 588.13% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 90.493% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 76.342% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 76.71% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 42.958% |
| Allakos Inc. | -24.97 Million USD | 10.759% |
| Imunon, Inc. | -4.21 Million USD | -428.922% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -51.187% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 83.539% |
| BioAtla, Inc. | -109.01 Million USD | 79.554% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 3127.989% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -2273.589% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 286.261% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -5.117% |
| XOMA Corporation | -29 Million USD | 23.145% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -34.589% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -147.205% |
| aTyr Pharma, Inc. | -7.44 Million USD | -199.208% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 82.118% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 89.293% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 72.746% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 75.973% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -2494.089% |
| Akari Therapeutics, Plc | -3.84 Million USD | -479.662% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1473.352% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.614% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1775.881% |
| UroGen Pharma Ltd. | 4.39 Million USD | 607.584% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 119.64% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 31071.902% |
| Orgenesis Inc. | 21.78 Million USD | 202.314% |
| Entera Bio Ltd. | -10.62 Million USD | -109.69% |
| GH Research PLC | -78.07 Million USD | 71.454% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 16.396% |
| Xencor, Inc. | 29.64 Million USD | 175.186% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -1031.479% |
| Replimune Group, Inc. | 1.41 Million USD | 1678.47% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -9000.56% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 82.369% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1775.881% |
| Portage Biotech Inc. | -4.98 Million USD | -347.46% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -98979.796% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 66.293% |
| OncoCyte Corporation | -6.56 Million USD | -239.601% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 2583.583% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -389.239% |
| Purple Biotech Ltd. | -14.13 Million USD | -57.646% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 6.179% |
| scPharmaceuticals Inc. | -6.54 Million USD | -240.535% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -33.524% |
| HilleVax, Inc. | -165.48 Million USD | 86.532% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -778.172% |
| Tharimmune, Inc. | -10.93 Million USD | -103.816% |
| Genprex, Inc. | -6.73 Million USD | -230.799% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 93.957% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 74.804% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1490.864% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -571.943% |
| OKYO Pharma Limited | -826.84 Thousand USD | -2595.538% |
| Savara Inc. | 153 Thousand USD | 14667.32% |
| Curis, Inc. | -23.88 Million USD | 6.694% |
| Daré Bioscience, Inc. | -5.15 Million USD | -332.113% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -2772.121% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -259.021% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 1980.844% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.011% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 280.638% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 96.335% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 87.99% |
| Erasca, Inc. | -37.21 Million USD | 40.112% |
| bluebird bio, Inc. | 108.57 Million USD | 120.529% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1630.579% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 105.885% |
| DBV Technologies S.A. | -126.98 Million USD | 82.448% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1630.579% |
| Moderna, Inc. | -2.9 Billion USD | 99.233% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -115.301% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -105.079% |
| Molecular Templates, Inc. | 707 Thousand USD | 3252.475% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 28.953% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 106.43% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 72.84% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 75.703% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 30.937% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 35.164% |
| MacroGenics, Inc. | -66.98 Million USD | 66.727% |
| RenovoRx, Inc. | -1.17 Million USD | -1800.085% |
| Adicet Bio, Inc. | -138.78 Million USD | 83.941% |
| Prime Medicine, Inc. | -27.94 Million USD | 20.232% |
| Aditxt, Inc. | 18.12 Million USD | 222.996% |
| Adagene Inc. | -87.62 Million USD | 74.565% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -435.071% |
| Quantum-Si incorporated | -118.55 Million USD | 81.201% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 161.903% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -198.2% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 54.054% |
| SciSparc Ltd. | -2.06 Million USD | -979.322% |
| Vericel Corporation | 1.27 Million USD | 1845.341% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -85.862% |
| Minerva Neurosciences, Inc. | 41 Million USD | 154.355% |
| Generation Bio Co. | 31.44 Million USD | 170.873% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 87.29% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 27.924% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 119.116% |
| Invivyd, Inc. | -198.47 Million USD | 88.77% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 75.31% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -829.562% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 68.515% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -226.564% |
| 2seventy bio, Inc. | 181.71 Million USD | 112.265% |
| ADMA Biologics, Inc. | 90.06 Million USD | 124.746% |
| Clene Inc. | 3.34 Million USD | 767.305% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -145.39% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -3.612% |
| GeoVax Labs, Inc. | -6.45 Million USD | -245.412% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 93.523% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 14.276% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 112.545% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -444.73% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 545.582% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -327.875% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 82.895% |
| Evaxion Biotech A/S | 5.28 Million USD | 521.575% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 80.2% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 83.022% |
| Trevena, Inc. | 2.25 Million USD | 1087.068% |
| Surrozen, Inc. | -32.66 Million USD | 31.766% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 56.731% |
| Cingulate Inc. | 3.08 Million USD | 823.007% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -658.87% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 410.115% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -139.882% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 71.902% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 83.045% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 78.882% |
| Clearmind Medicine Inc. | -3.94 Million USD | -465.307% |
| Kronos Bio, Inc. | -36.05 Million USD | 38.182% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 336.88% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1628.536% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 58.921% |
| Statera Biopharma, Inc. | 14.41 Million USD | 254.602% |
| ImmunityBio, Inc. | 618.22 Million USD | 103.605% |
| Korro Bio, Inc. | -132.94 Million USD | 83.235% |
| Kineta, Inc. | -4.54 Million USD | -390.817% |
| BioVie Inc. | -17.73 Million USD | -25.691% |
| Codexis, Inc. | -43.27 Million USD | 48.492% |
| Celularity Inc. | 65.19 Million USD | 134.189% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -603.313% |
| Celcuity Inc. | 6.78 Million USD | 428.562% |
| Virax Biolabs Group Limited | -3.36 Million USD | -562.359% |
| Cibus, Inc. | -8.07 Million USD | -175.91% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -427.028% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 587.702% |
| IN8bio, Inc. | -16.38 Million USD | -35.994% |
| Kodiak Sciences Inc. | -103.87 Million USD | 78.543% |
| Annexon, Inc. | -193.75 Million USD | 88.497% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 62011.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -27.367% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -534.443% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.114% |
| Eyenovia, Inc. | 1.25 Million USD | 1870.713% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 182.84% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -587.265% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 32.962% |
| Arcellx, Inc. | -296.95 Million USD | 92.495% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -14.262% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 62.144% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -7.531% |
| Moolec Science SA | 117.61 Thousand USD | 19049.803% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 41.957% |
| Geron Corporation | 14.76 Million USD | 250.992% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 41.221% |
| Royalty Pharma plc | 5.65 Billion USD | 100.394% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 84.24% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -218.882% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -315.599% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 84.163% |
| Humacyte, Inc. | -22.48 Million USD | 0.881% |
| Structure Therapeutics Inc. | -124.33 Million USD | 82.075% |
| 89bio, Inc. | -289.05 Million USD | 92.289% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 11.703% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -1150.028% |
| Genelux Corporation | -6.89 Million USD | -223.061% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 28.24% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 126.661% |
| Notable Labs, Ltd. | -9.77 Million USD | -127.987% |
| Liquidia Corporation | -80.17 Million USD | 72.201% |
| Mustang Bio, Inc. | -3.73 Million USD | -496.574% |
| Immunovant, Inc. | -635.22 Million USD | 96.491% |
| Quantum-Si incorporated | -118.55 Million USD | 81.201% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -26.896% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -437.968% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 377.663% |
| Acasti Pharma Inc. | -23 Million USD | 3.117% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -561.909% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -37.162% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 83.819% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -615.193% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -0.252% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -20.028% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 86.833% |
| PepGen Inc. | -60.67 Million USD | 63.264% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 2.994% |
| United Therapeutics Corporation | -507.7 Million USD | 95.61% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -16.532% |
| Solid Biosciences Inc. | -47.75 Million USD | 53.324% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -2485.348% |
| Immuneering Corporation | -54.94 Million USD | 59.434% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -430.226% |
| Silo Pharma, Inc. | -3.52 Million USD | -532.408% |
| Belite Bio, Inc | -87.27 Million USD | 74.461% |
| XOMA Corporation | -29 Million USD | 23.145% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 68.474% |
| Bionomics Limited | 227 Million USD | 109.818% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 80.833% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -779.905% |
| uniQure N.V. | -102.95 Million USD | 78.351% |
| Cassava Sciences, Inc. | -121.13 Million USD | 81.601% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -435.071% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 154.426% |
| Forte Biosciences, Inc. | -11.96 Million USD | -86.339% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -620.315% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 21126.415% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -587.265% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 350.286% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -200.539% |
| Altimmune, Inc. | -134.48 Million USD | 83.427% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 111.253% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -779.905% |
| Compugen Ltd. | -12.9 Million USD | -72.722% |
| Peak Bio, Inc. | 10.34 Million USD | 315.548% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -7775.618% |
| Benitec Biopharma Inc. | -50.58 Million USD | 55.937% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 78.639% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 213.454% |
| Zura Bio Limited | -99.8 Million USD | 77.669% |
| PolyPid Ltd. | 6.17 Million USD | 461.232% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 130.07% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 213.454% |
| Instil Bio, Inc. | 75.35 Million USD | 129.576% |
| argenx SE | -2.02 Billion USD | 98.901% |
| Immunome, Inc. | -97.02 Million USD | 77.03% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 0.92% |
| Verona Pharma plc | -220.44 Million USD | 89.889% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 68.934% |
| Shattuck Labs, Inc. | -121.42 Million USD | 81.644% |
| CervoMed Inc. | -7.79 Million USD | -186.006% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 87.985% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -409.673% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 83.082% |
| Moolec Science SA | 117.61 Thousand USD | 19049.803% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -874.136% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 240.19% |
| AnaptysBio, Inc. | -18.15 Million USD | -22.792% |
| Design Therapeutics, Inc. | -18.15 Million USD | -22.799% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 68.332% |
| NeurAxis, Inc. | 145.7 Thousand USD | 15397.186% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 298.433% |
| Lumos Pharma, Inc. | -28.49 Million USD | 21.777% |
| Achilles Therapeutics plc | -126.92 Million USD | 82.44% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 68.934% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -3298.96% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -7.289% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1628.536% |
| Nutriband Inc. | -251.65 Thousand USD | -8756.499% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -69.22% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -199.57% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 106.551% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 193.904% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 95.019% |
| Palisade Bio, Inc. | -12.06 Million USD | -84.763% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 84.115% |
| Beam Therapeutics Inc. | -262.72 Million USD | 91.517% |
| Neurogene Inc. | -131.95 Million USD | 83.109% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 202.164% |
| AEON Biopharma, Inc. | -4.88 Million USD | -356.721% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 94.091% |
| Sesen Bio, Inc. | -112.55 Million USD | 80.198% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 77.681% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -849.317% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 42.889% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 73.238% |
| Athira Pharma, Inc. | -88.99 Million USD | 74.957% |
| Vaccinex, Inc. | -1.28 Million USD | -1630.435% |
| HCW Biologics Inc. | 2.85 Million USD | 880.207% |
| XOMA Corporation | -29 Million USD | 23.145% |
| Nektar Therapeutics | 210.24 Million USD | 110.601% |
| Arvinas, Inc. | -313.8 Million USD | 92.897% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1473.352% |
| Merus N.V. | -192.88 Million USD | 88.445% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 137.156% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -221.245% |
| Rezolute, Inc. | -68.16 Million USD | 67.304% |
| Clene Inc. | 3.34 Million USD | 767.305% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -69.015% |
| BeyondSpring Inc. | -13.75 Million USD | -62.036% |
| Synlogic, Inc. | -6.68 Million USD | -233.403% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 2065.432% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -163.607% |
| Peak Bio, Inc. | 10.34 Million USD | 315.548% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 72.958% |
| Krystal Biotech, Inc. | -350.23 Million USD | 93.636% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 117.956% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 86.812% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -605.954% |
| MannKind Corporation | 143.89 Million USD | 115.489% |
| Ikena Oncology, Inc. | -109.15 Million USD | 79.582% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -194.386% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 32.665% |
| Gossamer Bio, Inc. | 180.35 Million USD | 112.358% |
| CohBar, Inc. | -5.93 Million USD | -275.805% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 25.077% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 588.13% |
| Legend Biotech Corporation | -949.39 Million USD | 97.652% |
| Mural Oncology plc | -255.84 Million USD | 91.288% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 169.185% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -373.141% |
| Disc Medicine, Inc. | -358.28 Million USD | 93.779% |
| Champions Oncology, Inc. | 4.81 Million USD | 563.175% |
| REGENXBIO Inc. | 54.76 Million USD | 140.695% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -8188.367% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 85.242% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -147.315% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 72.376% |
| Vaxart, Inc. | -8.24 Million USD | -170.453% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 55.584% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 82.473% |
| Cellectis S.A. | -43.85 Million USD | 49.178% |
| Longeveron Inc. | -2.9 Million USD | -666.437% |
| Repare Therapeutics Inc. | -107.85 Million USD | 79.336% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 102.302% |
| Inozyme Pharma, Inc. | 12 Million USD | 285.671% |
| Revolution Medicines, Inc. | -608.2 Million USD | 96.335% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -1712.033% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 91.593% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 85.148% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -42.443% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -2911.892% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.767% |
| Denali Therapeutics Inc. | -74.86 Million USD | 70.229% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -85.862% |
| Veru Inc. | 4.77 Million USD | 566.279% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -98.186% |
| Cingulate Inc. | 3.08 Million USD | 823.007% |
| Passage Bio, Inc. | 4.58 Million USD | 586.107% |
| Context Therapeutics Inc. | -14.44 Million USD | -54.244% |
| Exicure, Inc. | 5.84 Million USD | 481.057% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 90.325% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 43.675% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 242.043% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 62.109% |
| Nuvalent, Inc. | -335.38 Million USD | 93.355% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1385.099% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 70.076% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -150.709% |
| OmniAb, Inc. | 9.2 Million USD | 342.182% |
| Anew Medical, Inc. | 1.43 Million USD | 1655.919% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 236.054% |
| Lipocine Inc. | -4.75 Million USD | -368.768% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 79.706% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 246.333% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 56.004% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 189.539% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -231.617% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 66.142% |
| Ocugen, Inc. | -32.52 Million USD | 31.466% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 73.955% |
| Q32 Bio Inc. | -37.94 Million USD | 41.267% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -3449.045% |
| Alumis Inc. Common Stock | -13.52 Million USD | -64.742% |
| Equillium, Inc. | -22.39 Million USD | 0.464% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 12.829% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 31.688% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -8890.178% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 116.628% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 796.936% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 6885.998% |
| Dominari Holdings Inc. | 195 Thousand USD | 11529.744% |
| Edesa Biotech, Inc. | -5.26 Million USD | -323.17% |
| vTv Therapeutics Inc. | -8.91 Million USD | -149.95% |
| Bio-Techne Corporation | 267.74 Million USD | 108.324% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -37.504% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 81.127% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -165.239% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -76.176% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 90.907% |
| Nkarta, Inc. | 57.29 Million USD | 138.898% |
| BioCardia, Inc. | 212 Thousand USD | 10613.208% |
| Iterum Therapeutics plc | 13.43 Million USD | 265.858% |